HepaPredict AB is a contract research organization (CRO) specializing in drug metabolism and toxicity. We offer in-house evaluations of drug metabolism, pharmacokinetic properties and safety as well as drug target validations based on our novel long-term stable physiological 3D spheroid culture platform.

HepaPredict is the only company that provides this 3D spheroid platform for predictive in vivo metabolism and toxicity data using, integrated with preclinical solutions and scientific consultancy for drug discovery and optimized lead selection that result in:

1. Improved preclinical selection of drug candidates for clinical development
2. Shortened times and reduced costs of drug development times and
3. Development of novel medications against hepatic diseases

HepaPredict was founded in 2016 as a private spin-off from Karolinska Institutet, Stockholm, Sweden. Our ambition is to commission our scientific experience and expertise to deliver highest-quality science with the goal to support and optimize drug development efficacy and safety.